Brokers Set Expectations for Scholar Rock FY2030 Earnings

Scholar Rock Holding Corporation (NASDAQ:SRRK) – Research analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Scholar Rock in a report released on Monday, January 26th. HC Wainwright analyst A. Maldonado expects that the company will post earnings of $1.07 per share for the year. HC Wainwright has a “Buy” rating and a $58.00 price objective on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($2.42) per share.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.02). During the same period last year, the business earned ($0.66) earnings per share.

Several other analysts have also commented on SRRK. Barclays increased their price target on shares of Scholar Rock from $45.00 to $52.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. JPMorgan Chase & Co. increased their target price on Scholar Rock from $46.00 to $47.00 and gave the company an “overweight” rating in a report on Tuesday, November 18th. Truist Financial dropped their price target on Scholar Rock from $54.00 to $44.00 and set a “buy” rating for the company in a research report on Monday, October 20th. UBS Group started coverage on Scholar Rock in a research report on Wednesday, January 7th. They issued a “buy” rating and a $60.00 price objective on the stock. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $50.00 price objective on shares of Scholar Rock in a research note on Friday, November 14th. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Scholar Rock presently has an average rating of “Buy” and a consensus target price of $51.14.

Scholar Rock Stock Performance

NASDAQ:SRRK opened at $43.13 on Tuesday. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $4.40 billion, a P/E ratio of -13.69 and a beta of 0.63. The firm has a 50-day moving average price of $44.05 and a two-hundred day moving average price of $37.46. Scholar Rock has a twelve month low of $22.71 and a twelve month high of $48.28.

Insider Buying and Selling at Scholar Rock

In other news, insider Mo Qatanani sold 14,898 shares of Scholar Rock stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $46.71, for a total value of $695,885.58. Following the completion of the sale, the insider owned 85,660 shares of the company’s stock, valued at $4,001,178.60. The trade was a 14.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Caryn Parlavecchio sold 6,600 shares of the company’s stock in a transaction on Friday, January 16th. The shares were sold at an average price of $44.48, for a total value of $293,568.00. Following the completion of the transaction, the insider owned 148,864 shares of the company’s stock, valued at $6,621,470.72. The trade was a 4.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 305,687 shares of company stock valued at $13,540,573. 13.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of SRRK. Wellington Management Group LLP grew its holdings in Scholar Rock by 124.5% in the third quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock valued at $169,289,000 after purchasing an additional 2,521,022 shares during the period. Holocene Advisors LP acquired a new position in shares of Scholar Rock in the 3rd quarter valued at $91,670,000. Norges Bank purchased a new stake in shares of Scholar Rock during the 2nd quarter valued at $41,628,000. Balyasny Asset Management L.P. purchased a new stake in shares of Scholar Rock during the 2nd quarter valued at $33,062,000. Finally, UBS Group AG increased its holdings in shares of Scholar Rock by 233.8% during the 3rd quarter. UBS Group AG now owns 1,131,787 shares of the company’s stock worth $42,148,000 after buying an additional 792,760 shares during the last quarter. 91.08% of the stock is currently owned by hedge funds and other institutional investors.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).